Durvalumab in Pediatric and Adolescent Patients

Part of paid clinical trials in Los Angeles, California.

Sponsor
Leo Mascarenhas
Study ID
NCT02793466
Phase
PHASE1
Status
Completed

Conditions

  • Central Nervous System Tumors
  • Lymphoma
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
1 Year - 17 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This clinical trial is the first clinical trial to study Durvalumab, a checkpoint inhibitor which stimulates the patient's own immune system to act against cancer cells in children and adolescents. This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

Key Dates

Start date
Jul 31, 2016
Status verified
Sep 2023
Primary completion
Nov 30, 2022
Completion
Apr 30, 2023

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab; MEDI4736
    Open label

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Children's Hospital Los AngelesLos AngelesCalifornia90027-

Find similar trials in Los Angeles, CA

By research site
Children's Hospital Los Angeles· Los Angeles, CA

Related Studies